Kestra Medical Technologies (NASDAQ:KMTS) Given New $32.00 Price Target at BTIG Research

Kestra Medical Technologies (NASDAQ:KMTS) had its price objective hoisted by BTIG Research from $30.00 to $32.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price target would suggest a potential upside of 32.34% from the stock’s previous close.

Other analysts also recently issued reports about the company. The Goldman Sachs Group reduced their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Wall Street Zen raised shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Weiss Ratings upgraded shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 30th. Finally, Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a report on Wednesday. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $27.83.

Kestra Medical Technologies Trading Down 2.3%

Shares of KMTS stock opened at $24.18 on Wednesday. Kestra Medical Technologies has a 12-month low of $13.25 and a 12-month high of $30.00. The company has a market capitalization of $1.41 billion, a PE ratio of -6.11 and a beta of 0.47. The firm has a 50 day moving average price of $22.09 and a two-hundred day moving average price of $22.75. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.15.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The firm had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. As a group, analysts predict that Kestra Medical Technologies will post -2.34 earnings per share for the current year.

Insider Buying and Selling at Kestra Medical Technologies

In other news, insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $20.81, for a total transaction of $312,150.00. Following the completion of the sale, the insider owned 395,467 shares of the company’s stock, valued at approximately $8,229,668.27. This represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System lifted its stake in Kestra Medical Technologies by 39.2% during the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock worth $555,000 after purchasing an additional 7,844 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Kestra Medical Technologies by 6.6% during the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after buying an additional 5,731 shares in the last quarter. Quantinno Capital Management LP acquired a new position in shares of Kestra Medical Technologies during the 1st quarter worth $431,000. Sei Investments Co. lifted its position in shares of Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after buying an additional 43,753 shares during the last quarter. Finally, Spartan Wealth Advisory Services LLC acquired a new stake in Kestra Medical Technologies in the first quarter valued at about $603,000.

Kestra Medical Technologies News Summary

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra secured up to $200 million in non-dilutive financing through a five-year term loan facility, which should strengthen its balance sheet and support growth without issuing new shares. Article Title
• Positive Sentiment: The company lifted FY2027 revenue guidance to about $137 million, above Wall Street expectations, and said it is targeting 70%+ gross margins over the next few years, signaling a more promising long-term path to profitability. Article Title
• Neutral Sentiment: Kestra reported fourth-quarter revenue of $28.64 million, which topped estimates, showing continued commercial traction even as profitability remains negative. Article Title
• Neutral Sentiment: The company’s Q4 earnings call and transcript may give investors more detail on management’s growth and margin plans, but the main market-moving themes today were the earnings miss, raised outlook, and financing announcement. Article Title
• Negative Sentiment: Kestra posted a quarterly loss of $0.67 per share, wider than the $0.59 loss analysts expected, reinforcing concerns that the company is still burning cash and has yet to reach profitability. Article Title

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.